The impact of different antimicrobial exposures on the gut microbiome in the ARMORD observational study

Leon Peto,[1,2*] Nicola Fawcett,[1,2] Musaiwale M Kamfose,[1] Claire Scarborough,[1] Andy Peniket,[1] Robert Danby,[1,4] Tim EA Peto,[1,2,3] Derrick W Crook,[1,2,3] Martin J Llewelyn[5,6†], A Sarah Walker[1,2,3†]

[1] Oxford University Hospitals NHS Foundation Trust, Oxford, UK

[2] Nuffield Department of Medicine, University of Oxford, Oxford, UK

[3] NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, UK

[4] Anthony Nolan Research Institute, Royal Free Hospital, Hampstead, London, UK

[5] Brighton and Sussex Medical School, Falmer, UK

[6] University Hospitals Sussex NHS Foundation Trust, Brighton, UK.

* Corresponding author: Department of Microbiology, John Radcliffe Hospital, Oxford, OX3 9DU; leon.peto@ndm.ox.ac.uk

[†] Contribution equal

Abstract

Background: Better metrics to compare the impact of different antimicrobials on the gut microbiome would aid efforts to control antimicrobial resistance (AMR).

Methods: The Antibiotic Resistance in the Microbiome – Oxford (ARMORD) study recruited inpatients, outpatients and healthy volunteers in Oxfordshire, UK, who provided stool samples for metagenomic sequencing. Data on previous antimicrobial use and potential confounders were recorded. Exposures to each antimicrobial were considered as factors in a multivariable linear regression, also adjusted for demographics, with separate analyses for those contributing samples cross-sectionally or longitudinally. Outcomes were Shannon diversity and relative abundance of specific bacterial taxa (*Enterobacteriaceae*, *Enterococcus*, and major anaerobic groups) and antimicrobial resistance genes (targeting beta-lactams, tetracyclines, aminoglycosides, macrolides, and glycopeptides).

Results: 225 adults were included in the cross-sectional analysis, and a subset of 79 patients undergoing haematopoietic stem cell transplant provided serial samples for longitudinal analysis. Results were largely consistent between the two sampling frames. Recent use of piperacillin-tazobactam, meropenem, intravenous co-amoxiclav and clindamycin were associated with large reductions in microbiome diversity and reduced abundance of anaerobes. Exposure to piperacillin-tazobactam and meropenem were associated with a decreased abundance of *Enterobacteriaceae*, and an increased abundance of *Enterococcus* and major AMR genes, but there was no evidence that these antibiotics had a greater impact on microbiome diversity than iv co-amoxiclav or oral clindamycin. In contrast, co-trimoxazole, doxycycline, antifungals and antivirals had less impact on microbiome diversity and selection of AMR genes.

Conclusion: Simultaneous estimation of the impact of over 20 antimicrobials on the gut microbiome and AMR gene abundance highlighted important differences between individual drugs. Some drugs in the WHO Access group (co-amoxiclav, clindamycin) had similar magnitude impact on microbiome diversity to those in the Watch group (meropenem, piperacillin-tazobactam) with potential implications for acquisition of resistant organisms. Metagenomic sequencing can be used to compare the impact of different antimicrobial agents and treatment strategies on the commensal flora.

Introduction

Effective antimicrobial stewardship is necessary to limit the emergence and spread of antimicrobial resistance (AMR),[1] and this includes the preferential use of agents least likely to select for drug resistant pathogens among the commensal flora. This typically consists of avoiding "broad" spectrum antimicrobials, as well as those to which resistance is currently rare, and these principles underlie the World Health Organisation AWaRe classification (Access, Watch and Reserve).[2] AWaRe is reflected in the current UK National Health Service standard contract, which requires hospitals to increase the proportion of "Access" antibiotics used, replacing previous requirements to reduce overall antibiotic use.[3] However, these classifications are largely based on activity against pathogens rather than direct measures of AMR gene selection or microbiome disruption, and stewardship could be improved if such measures were available. For example, two antibiotics being considered for use may have similar spectra against a target pathogen, but very different impacts on AMR selection, either because the amounts reaching the commensal flora differ, or because they have differing spectra against non-pathogenic commensals that protect against colonisation with drug-resistant pathogens. Metagenomic sequencing provides a direct measure of AMR genes and microbiome composition in a sample, and its increasing availability in recent years is starting to allow the fuller impacts of antimicrobials to be measured.

The large intestine contains the vast majority of human commensal bacteria and is the primary reservoir for several clinically important commensal pathogens, particularly the *Enterobacteriaceae* (including *Escherichia coli* and *Klebsiella pneumonia*) and *Enterococcus faecium*. Increasing multi-drug resistance in these organisms represents a major global public health challenge.[4,5] Existing evidence linking antibiotic exposure to individual-level selection for AMR in the gut flora comes predominantly from small, healthy volunteer studies, which have shown that antibiotics can cause rapid microbiome disruption, but provide limited comparative data between antibiotics. They also may also have limited applicability to real patients, who often have recent exposure to several different agents and are at high risk of colonisation with drug resistant organisms. Randomised trials are a robust method to assess the impacts of different treatment approaches, but few have reported microbiome outcomes.[6–9] Another approach is to exploit variation in routine use of antibiotics in groups of patients at high risk of AMR to understand the nature and extent of differences between agents which cannot easily be achieved in other designs. Here we report results from a prospective observational study assessing the impact of antimicrobial use on the gut microbiome and selection of AMR genes. This study included two different sampling frames to produce independent and complimentary estimates, one cross-sectional, analysing a single stool sample from each participant, and one longitudinal, analysing changes in serial samples taken from the same participant admitted for haematopoietic stem cell transplant to enrich for broad spectrum antimicrobial exposure.

Methods

Study design and participants

The Antibiotic Resistance in the Microbiome – Oxford (ARMORD) study was an observational study that recruited healthy individuals living in Oxfordshire, and patients at the Oxford University Hospitals NHS Foundation Trust (OUH). The study was coordinated by the Nuffield Department of Medicine, University of Oxford, and was approved by the East Midlands-Leicester Central Research Ethics Committee (15/EM/0270).

The study involved two sampling strategies:
i) *Cross-sectional sampling*. Participants provided a single stool sample, and measures of the microbiome and AMR gene abundance were related to exposures recorded at the time of sampling.
ii) *Longitudinal sampling.* Participants provided serial stool samples, and changes in the microbiome and AMR gene abundance between serial samples from the same individual were related to exposures between samples. Longitudinal sampling was only performed in patients admitted to the OUH haematology ward for haematopoietic cell transplant (HCT). The initial sample collected from these patients was also used in the cross-sectional analysis.

Participants were eligible if they were ≥18 years old, had no stoma or active inflammatory bowel disease, and were able to give informed consent and provide a history of recent antibiotic use. General medical inpatients and outpatients at OUH were approached by a member of the study team during routine care (without regard to the reason for admission or attendance), and healthy individuals responded to articles in local media. After providing written informed consent, participants were interviewed and their medical notes were reviewed to collect information about antimicrobial exposures in the past year, recent travel, diet, alcohol and tobacco use, animal exposures, healthcare exposure and use of specific drugs (case report form in Appendix p8). Electronic patient records available at OUH included i) inpatient, emergency department and outpatient attendances, ii) inpatient and discharge antimicrobial prescriptions iii) microbiology, haematology and biochemistry results, iv) inpatient clinical observations (used to calculate the National Early Warning Score 2 [NEWS2] summary score of physiological abnormality),[10] and v) discharge coding (including Charlson co-morbidity index).

Sample collection

In the cross-sectional stratum, participants were asked to provide the first stool sample passed after recruitment. This was stored at ambient temperature for a maximum of 24 hours before being frozen at -80˚C. In the longitudinal stratum, participants were asked to provide a stool sample every other day until discharge. These were stored at 4-8˚C for up to 72 hours before being frozen at -80˚C.

132

133 **DNA extraction, sequencing and bioinformatic analysis**

134 DNA extraction was performed by bead beating in Lysing Matrix E tubes (MP Biomedicals)
135 followed by QIAGEN Fast DNA Stool MiniKit (QIAGEN) (details in Appendix p1). Samples
136 were sequenced in batches of 56-114 at the Oxford Centre for Genomics, and had
137 automated normalisation and library preparation using either NEBNext Ultra or NEBNext
138 Ultra II FS kits. All samples from the same batch were pooled and sequenced across 2-8
139 Illumina HiSeq4000 lanes using 150bp paired-end sequencing. Following human read
140 removal all samples were subsampled to a depth of 3.5 million paired reads, and samples
141 with fewer reads were excluded. Taxonomic classification was performed with MetaPhlAn2
142 (for diversity indices) and Kraken2 (for abundance of specific taxa). AMR gene detection in
143 metagenomic sequence data was performed with the ARIBA software package, using the
144 CARD database and ontology (v3.0.2) (details in Appendix p2).

145

146 **Outcomes**

147 Sequence data was used to derive three types of outcome (further details in Appendix p3):
148 i) *Shannon diversity index* - a single metric of diversity for each sample (calculated as the
149 sum of p*ln(p) for all species, where p is proportional abundance). This index incorporates
150 relative abundance and the number of species detected (richness).
151 ii) *Log relative abundance of specific bacterial taxa*. The taxa of interest were two major
152 groups of opportunistic pathogens (family *Enterobacteriaceae* and genus *Enterococcus*), and
153 three major groups of anaerobes that make up the majority of the gut microbiome in most
154 people but are largely non-pathogenic, so may be important for colonisation resistance
155 (phyla Bacteroidetes and Actinobacteria, and class Clostridia). Relative abundance was the
156 proportion of reads in the sample that mapped to a group. If a particular taxon was not
157 detected, its relative abundance was imputed as 10^{-6} (i.e. a pseudocount at the approximate
158 lower limit of detection).
159 iii) *Log relative abundance of specific classes of AMR genes*. Five classes of clinically
160 important resistance mechanisms were of interest: Clinically significant beta-lactamases
161 (CTX-M, OXA, TEM, SHV), tetracycline ribosomal protection proteins, aminoglycoside
162 transferases (AAC, ANT, APH), macrolide/clindamycin resistance genes (erm and mef), and
163 the vanA vancomycin resistance gene. If a particular gene was not detected its relative
164 abundance was imputed as 10^{-5} (i.e. a pseudocount at the approximate lower limit of
165 detection).

166

167

168 **Statistical analysis**

169 A separate model was fitted for each of the eleven outcomes (Shannon diversity, five
170 bacterial taxa, and five classes of AMR genes, as above). Model results are presented side-

171 by-side for the five bacterial taxa, and for the five AMR gene classes. For bacterial taxa and
172 AMR genes the outcomes are relative (not absolute) abundance, so the effects of
173 antimicrobials on different taxa/genes are not independent (e.g. if the only effect of an
174 antimicrobial was to eradicate one major taxon and leave the absolute abundances of
175 others unchanged, then the relative abundances of these other taxa would increase).
176 Analysis was performed in R v4.2.3.
177
178 *Cross-sectional sampling frame*
179 Multivariable linear regression was used to estimate the effects of specific antimicrobial
180 exposures on the outcomes above. Covariates were: age, sex, participant category (healthy,
181 general medical, autologous stem cell transplant, allogeneic stem cell transplant), days of
182 chemotherapy received (0 for non-HCT participants, truncated at 14), maximum Charlson
183 comorbidity score in the year before sampling (identified from electronic health records),
184 and the following physiological abnormalities in the fortnight prior to sample collection;
185 maximum NEWS2 score, C-reactive protein (CRP) >50 mg/dL, white cell count (WCC) >11
186 $x10^9$/L, and WCC <0.5 $x10^9$/L. Healthy volunteers lived in the OUH catchment area but most
187 had no previous activity at OUH, and in this case normal values were imputed (i.e. Charlson
188 Index 0, NEWS2 score 0, CRP <50 mg/dL, WCC <11 and >0.5 $x10^9$/L). Other covariates such
189 as diet and travel were not included in the final model, as they were not significantly
190 associated with Shannon diversity in multivariable analysis and their inclusion did not
191 materially affect other estimates. We did not make a formal adjustment for multiple testing,
192 and present unadjusted p-values which should be interpreted in the light of the number of
193 outcomes (11) and antimicrobials (21) considered. Many of the antibiotic exposures were
194 correlated or reflected iv/oral administrations of antimicrobials from the same class, and we
195 considered relative abundances as described above, meaning that it is not straightforward
196 to correct for multiple testing without being overly conservative. We therefore chose to
197 interpret the findings as exploratory in the context of the supporting level of evidence, the
198 number of comparisons performed and consistency across outcomes.
199
200 All antimicrobial exposures observed in >5 participants were included in the model.
201 Individual agents were categorised separately if given by different administration routes
202 (e.g. oral vancomycin and intravenous vancomycin), but route of administration was ignored
203 in analyses of antimicrobial class (e.g. glycopeptides). In categorising antimicrobial class,
204 beta-lactams were divided into 'narrow spectrum' (defined as penicillin, amoxicillin,
205 flucloxacillin and first generation cephalosporins) and 'broad spectrum' (all others).
206 Exposure to each antimicrobial was included as a separate variable on a scale of 0 (no
207 exposure) to 1 (full exposure). In order to reflect both recency and total duration of
208 antimicrobial use, this exposure was modelled as the area under an exponential decay curve
209 of the form $y = 2^{-x/\lambda}$, in which λ is the microbiome disruption half-life, and x is time before
210 sample collection. A single value of λ was used for all analyses, chosen as the common value

211 across all antimicrobial exposures with the lowest Akaike Information Criterion across 1 to
212 14 days in the cross-sectional model for microbial diversity (6 days; Supplementary Table 1).
213 The disruption half-life of 6 days means that after 6 days of an antibiotic course a patient
214 would have an exposure of 0.5 to that agent, and after 12 days they would have an
215 exposure of 0.75. Details of the exposure calculation, including graphical depictions are in
216 the Appendix (p3 and Supplementary Figures 1-2).
217
218 *Longitudinal sampling frame*
219 Serial samples collected from participants undergoing HCT were used for the longitudinal
220 analysis. The unit of analysis was a pair of consecutive samples collected from the same
221 individual. For patients with >2 samples, each consecutive pair was used (i.e. sample 2 in
222 pair 1 was sample 1 in pair 2, and so on, so the total number of pairs per participant is one
223 less than the number of samples). Only pairs of samples collected within 2-30 days of each
224 other were used. A multivariable linear regression model was used that was analogous to
225 the cross-sectional model described above, except that the outcome was the *change*
226 between the first and second samples in a pair, rather than absolute values (i.e. change in
227 Shannon diversity, or change in log relative abundance of bacterial taxa or AMR genes).
228 Because pairs of samples from the same participant may not be independent of one
229 another, robust standard errors were used to allow for possible clustering.
230
231 Covariates were: age, sex, type of transplant (allogeneic or autologous), days of
232 chemotherapy received at collection of sample 1 (0 in non-HCT patients, and truncated at
233 14), number of days between sample 1 and sample 2, change in NEWS2 score between
234 sample 1 and sample 2, and the presence of the following new physiological abnormalities
235 recorded after collection of sample 1 and before collection of sample 2; CRP >50 mg/dL,
236 WCC >11 $x10^9$/L, WCC<0.5 $x10^9$/L. For each outcome, the value for the first sample in the
237 pair was also included as a covariate (i.e. baseline diversity or log relative abundance of
238 taxa/AMR genes).
239
240 Antimicrobial exposures were calculated for samples as in the cross-sectional analysis
241 above, and the exposure for each pair was the difference between the first and second
242 samples. This has the following implications: i) if a patient starts an antimicrobial after the
243 first sample is collected then the exposure for that pair is the same as for sample 2, ii) if a
244 patient is on long-term antimicrobial treatment then the exposure for a pair is zero (as one
245 would not expect this to lead to a difference between samples), iii) if a patient stops
246 antimicrobial treatment shortly after sample 1 then the exposure to that agent will be
247 negative (as one expects gut microbiome diversity to increase after stopping an
248 antimicrobial). Truncating the small number of negative values at zero had little impact on
249 results (data not shown).
250

Results

Between July 2015 and November 2018, 225 participants were recruited and had at least one sequenced stool sample, all of whom were included in the cross-sectional analysis (Table 1 and Supplementary Figure 3 [CONSORT diagram]). Thirty-three (15%) were healthy volunteers, 91 (40%) were general medical patients (84 acute admissions and 7 attending general outpatient clinics), and 101 (45%) were HCT patients. The healthy volunteers were on average younger, more likely to be female, and rarely had recent antibiotic exposure. In contrast, 184/192 (96%) of medical and haematology patients had received antibiotics in the past year, and 97 (51%) of these were receiving antibiotics at the time of sampling. Of those with antibiotic exposure in the past month, 99/148 (67%) had received >1 type of antimicrobial. Of 101 HCT participants in the cross-sectional analysis, 79 had >1 sequenced sample and so also contributed to the longitudinal analysis, and 173 sample pairs were included in this analysis. Bacteroidetes and Clostridia were predominant in most sequenced samples, and along with Actinobacteria, *Enterobacteriaceae* and *Enterococcus* accounted for a median 91% of classified organisms in baseline samples (Supplementary table 2). All these taxa were detected in all samples, apart from three samples with no detectable *Enterobacteriaceae*. The clinically significant AMR mechanisms included in this analysis were frequently detected: beta-lactamases in baseline samples from 67 (30%) patients, tetracycline AMR genes in 214 (95%), aminoglycoside transferases in 166 (74%), macrolide/clindamycin AMR genes in 210 (93%) and vanA in 31 (14%). Microbiome and resistome profiles of all samples are included in the Supplementary Data.

Impact of antimicrobial exposures on gut microbiome diversity

A half-life of 6 days was identified as the best fit for the antimicrobial exposure in the cross-sectional model of microbiome diversity, and this value was used for all subsequent analyses (Supplementary table 1). The independent effects of antimicrobial exposure on gut microbiome diversity in the cross-sectional and longitudinal models are shown in Figure 1. The cross-sectional model (Figure 1A) provided more precise estimates of microbiome disruption than the longitudinal model, and four antimicrobial exposures were associated with a significant reduction in gut Shannon diversity: iv co-amoxiclav (-3.0 [95% Confidence Interval -4.7 to -1.4 ; p = 0.0005), iv piperacillin-tazobactam (-2.6, [-3.4 to -1.8]; $p < 10^{-9}$), oral clindamycin (-2.2 [-3.5 to -0.8]; p = 0.002), and iv meropenem (-1.6 [-2.6 to -0.5]; p = 0.003). There was no evidence that the impact of iv co-amoxiclav was greater than iv meropenem (p=0.13). In contrast, co-trimoxazole and doxycycline were associated with minimal reductions in gut microbiome diversity, as were azole antifungals and acyclovir (lower 95% CI above -1.0). In the longitudinal analysis (Figure 1B), only five exposures had data from more than 20 sample pairs, and these were consistent with the cross-sectional results, including large reductions in diversity associated with exposure to piperacillin-tazobactam (-3.9 [-5.0 to -2.9]; $p < 10^{-10}$) and meropenem (-3.0 [-4.1 to -1.9]; $p < 10^{-6}$) (data

290 on iv co-amoxiclav and oral clindamycin insufficient for comparison). In the longitudinal
291 model, gentamicin was associated with marginally increased gut microbiome diversity (+6.6
292 [+1.3 to +11.8]; p = 0.02).
293
294 Analyses by antimicrobial class were also largely consistent between cross-sectional and
295 longitudinal analyses (Supplementary Figure 4). In both analyses narrow spectrum beta-
296 lactams were associated with substantially lower microbiome disruption than broad
297 spectrum beta-lactams. In the cross-sectional analysis, several other classes of antibiotics
298 also had little to no impact on the microbiome diversity; antifolates, macrolides,
299 aminoglycosides and tetracyclines (lower 95% CI above -1.0).
300
301 **Effects of antimicrobials on the abundance of specific taxa and AMR genes**
302 Piperacillin-tazobactam, meropenem, and ciprofloxacin were associated with significant
303 decreases in the relative abundance of *Enterobacteriaceae* in both models, as were
304 ceftriaxone and ceftazidime in the cross-sectional model (>1,000 fold decreased relative
305 abundance, p<0.01, Figure 2 & Supplementary Figure 5). There was no evidence of effects of
306 iv co-amoxiclav (p=0.90) or oral clindamycin (p=0.31) on relative abundance of
307 *Enterobacteriaceae*. Piperacillin-tazobactam and meropenem were also associated with
308 large increases in the relative abundance of *Enterococcus* in both models (>100 fold
309 increased relative abundance, p<0.01), as were iv co-amoxiclav (p=0.04), iv ceftriaxone
310 (p=0.02) and iv vancomycin (p=0.03) in the cross-sectional model. Many antibiotics were
311 associated with large reductions in the relative abundance of major anaerobe groups,
312 particularly Actinobacteria (reductions in which were associated with exposure to
313 ceftazidime, oral ciprofloxacin, oral clindamycin, iv co-amoxiclav, meropenem, piperacillin-
314 tazobactam, and iv vancomycin). When analysed by antimicrobial class, broad spectrum
315 beta-lactams were associated with reductions all anaerobe groups (Supplementary Figure
316 5).
317
318 Several antimicrobial exposures were also associated with increases in the relative
319 abundance of AMR genes (Figure 3, Supplementary Figure 6). In the cross-sectional analysis,
320 iv piperacillin-tazobactam and meropenem were both associated with increases in several
321 AMR mechanisms, including aminoglycoside transferases and macrolide resistance genes
322 (all p<0.02) but there was no evidence that these antibiotics had any effect on overall
323 relative abundance of beta-lactamases (p≥0.14), potentially reflecting lower abundance of
324 relevant species (see above) but greater AMR gene carriage in those surviving. In the cross-
325 sectional model, exposure to several classes of antimicrobials were associated with an
326 increase in the abundance of corresponding resistance genes, including glycopeptides,
327 tetracyclines, macrolides and clindamycin (all p≤0.02). Broad-spectrum beta-lactam use was
328 not associated with an increase in the abundance of beta-lactamases, but it was associated
329 with an increase in the abundance of glycopeptide and aminoglycoside AMR genes (both

330 p≤0.0001). Increased aminoglycoside AMR gene abundance was also associated with
331 clindamycin and glycopeptide use (both p≤0.02), but not aminoglycoside use.
332

333 ## Discussion

334 Our findings demonstrate that simultaneous modelling of multiple antimicrobial exposures
335 in a heterogeneous and heavily antibiotic exposed population can produce direct,
336 quantitative comparisons of the impact of different agents on multiple aspects of the gut
337 microbiome. Several broad-spectrum antibiotics were associated with large and rapid
338 reductions in gut microbiome diversity, including decreased abundance of several major
339 anaerobe groups, and increased abundance of *Enterococcus* species, along with
340 glycopeptide and aminoglycoside resistance mechanisms often found in *Enterococcus*
341 *faecium*.[5] The plausibility of these results is reinforced by the consistency between the two
342 independent analysis frameworks that were used; cross-sectional and longitudinal.
343 Microbiome disruption was clearest with clindamycin and broad spectrum beta-lactams
344 including iv co-amoxiclav, piperacillin-tazobactam, and meropenem, consistent with some
345 previous microbiome studies of these drugs.[11–14] This is also in keeping with estimates of
346 risk of *Clostridioides difficile* infection (CDI) which is highest with clindamycin,
347 fluoroquinolones, carbapenems and third-generation cephalosporins.[15,16] The limited
348 impact of doxycycline on diversity is also consistent with the lower risk of CDI observed with
349 tetracyclines. The decreased relative abundance of *Enterobacteriaceae* seen in this study
350 with piperacillin-tazobactam, ceftriaxone, meropenem, and ciprofloxacin correspond with
351 reductions seen in culture based studies.[17] The absence of any clear effect of beta-lactams
352 on the abundance of beta-lactamase gene abundance may be because there were too few
353 patients in this study to create robust categories of beta-lactamase by resistance spectrum,
354 so opposite impacts on different beta-lactamase genes would have been combined.
355
356 Observational studies of the gut microbiome allow large numbers of patients to be recruited
357 much more easily than interventional studies such as clinical trials. However, using data
358 from these to inform antibiotic usage is complicated by potential biases from confounding,
359 and because of difficulties in accurately modelling multiple exposures in patients receiving
360 many different antibiotics. In ARMORD, the apparent impact of vancomycin and
361 clarithromycin on diversity was substantially reduced when adjusting for other antibiotic
362 exposures (Figure 1A), in keeping with the fact that these drugs are often given alongside
363 broad-spectrum beta-lactams in the UK. Nevertheless, the complexity of antibiotic exposure
364 captured in observational data also more closely reflects real life, whereas clinical trials
365 generally manipulate one single antibiotic, and restrict background antibiotic exposure to
366 produce a cleaner, but potentially less generalisable, comparison.
367

368 The large degree of inter-individual variation in the gut microbiome introduces an additional
369 source of variation to cross-sectional studies compared to longitudinal sampling. Despite
370 this, cross-sectional sampling in ARMORD generally gave more precise estimates than
371 longitudinal sampling, despite using a similar number of samples. Recruiting any
372 hospitalised patients for longitudinal sampling before they have received antibiotics is
373 challenging, and this was true in ARMORD, even among patients admitted electively for
374 HCT. In ARMORD the quasi-experimental approach of longitudinal sampling starting before
375 antimicrobial exposure had no advantage over cross-sectional sampling, and complicated
376 recruitment.
377
378 The ARMORD study has important limitations. Short-read sequencing was used, meaning
379 the genetic context of AMR genes is uncertain, for example if they are associated with
380 mobile genetic elements or present in opportunistic pathogens.[23] Along with age and sex,
381 several markers of acute illness and comorbidity were included in the model to adjust for
382 potential confounding, but there may be residual and unmeasured confounding related to
383 factors not adequately represented in the model. This could explain some inconsistencies in
384 the effect of specific exposures between the cross-sectional and longitudinal estimates,
385 such as the impact of vancomycin on microbiome composition. The microbiome disruption
386 half-life used was 6 days, as this value best fitted the overall data, which implies that the
387 majority of the disruption and recovery of the bowel flora diversity occurs rapidly after
388 starting and stopping antimicrobials (Supplementary Figure 2). This is in keeping with
389 interventional studies in volunteers,[13,18] but is a simplification that does not account for
390 some longer term impacts of antibiotic use that can be detected months after treatment, in
391 particular the presence or absence of individual species or AMR genes.[19–21] A larger study
392 would allow more complex exposure models to be explored, as well as more granular
393 analyses at the level of individual species or resistance genes. Also, because the study was
394 observational, no data were available on drugs that are not commonly used at OUH,
395 including imipenem, cefepime and aztreonam, and few data were available for some other
396 drugs, such as clindamycin, limiting the reliability of these estimates. The study focussed on
397 participants with healthcare exposure, as it is this setting where antimicrobials are mostly
398 likely to be used and where microbiome disruption or AMR selection are of most
399 consequence. However, this limited its ability to assess the impact of some potentially
400 relevant exposures that were uncommon in our population such as recent foreign travel,
401 which is associated with the acquisition of AMR genes.[22] Finally, although we estimate the
402 independent effects of multiple exposures, the uncertainty is still large making it challenging
403 to use these results to adequately inform clinical use, as this would require clear distinction
404 between antibiotics that might be given for the same indication. For example, the cross-
405 sectional data are consistent with an identical average reduction in diversity with
406 piperacillin-tazobactam, meropenem, ceftazidime, ceftriaxone, intravenous co-amoxiclav,

407 ciprofloxacin and clindamycin, but they are also consistent with important differences
408 between these drugs. A larger study is required to identify or rule out such differences.
409
410 Overall, however, simultaneous estimation of the impact of over 20 antimicrobials on the
411 gut microbiome and AMR gene abundance highlighted important differences between
412 individual drugs, and that some drugs in the WHO Access group (co-amoxiclav, clindamycin)
413 had similar magnitude impact on microbiome diversity to those in the Watch group
414 (meropenem, piperacillin-tazobactam) with potential implications for acquisition of other
415 resistant organisms. The consistency of the ARMORD results between sampling frames and
416 with previous studies supports the wider use of observational metagenomic studies to
417 compare the impact of antimicrobials on the gut microbiome. Although some challenges
418 remain, such as identifying an optimal measure of antimicrobial exposure, this is a practical
419 approach to inform future research and stewardship.
420

Acknowledgements and funding

We would like to thank all the participants who took part in ARMORD, and also the nurses, healthcare support workers, and doctors on the OUH Haematology ward for their help with this study. This work was supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at Oxford University in partnership with the UK Health Security Agency (NIHR200915), and the NIHR Biomedical Research Centre, Oxford. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health or the UK Health Security Agency. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Declaration of interests

No authors have no conflict of interest to declare.

Availability of data and code

The data and code used to produce this manuscript are available in the supplementary material, including processed microbiome data, and pseudonymised patient metadata. The sequence data for this study have been deposited in the European Nucleotide Archive (ENA) at EMBL-EBI under accession number PRJEB86785.

440 **References**

441 1. O'Neill, J. *The Review on Antimicrobial Resistance*. https://amr-review.org/ (2016).

442 2. Sharland, M. *et al.* The WHO AWaRe Antibiotic Book: providing guidance on optimal

443 use and informing policy. *Lancet Infect Dis* **22**, 1528–1530 (2022).

444 3. NHS England » World Antimicrobial Awareness Week (WAAW) 2022.

445 https://www.england.nhs.uk/long-read/world-antimicrobial-awareness-week-waaw-2022/.

446 4. Ruppé, É., Woerther, P.-L. & Barbier, F. Mechanisms of antimicrobial resistance in

447 Gram-negative bacilli. *Ann Intensive Care* **5**, 61 (2015).

448 5. Miller, W. R., Munita, J. M. & Arias, C. A. Mechanisms of antibiotic resistance in

449 enterococci. *Expert Rev Anti Infect Ther* **12**, 1221–1236 (2014).

450 6. Edlund, C. *et al.* The clinical and microbiological efficacy of temocillin versus

451 cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal

452 microbiota: a randomised multicentre clinical trial in Sweden. *Lancet Infect Dis* **22**, 390–400

453 (2022).

454 7. Reyman, M. *et al.* Effects of early-life antibiotics on the developing infant gut

455 microbiome and resistome: a randomized trial. *Nat Commun* **13**, 893 (2022).

456 8. Vehreschild, M. J. G. T. *et al.* An open randomized multicentre Phase 2 trial to assess

457 the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized

458 patients treated with fluoroquinolones. *J Antimicrob Chemother* **77**, 1155–1165 (2022).

459 9. Pickering, H. *et al.* Impact of azithromycin mass drug administration on the

460 antibiotic-resistant gut microbiome in children: a randomized, controlled trial. *Gut Pathog*

461 **14**, 5 (2022).

462 10. Royal College of Physicians. *National Early Warning Score (NEWS) 2. Updated Report*
463 *of a Working Party*. https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-
464 score-news-2 (2017).
465 11. Rashid, M.-U. *et al.* Determining the Long-term Effect of Antibiotic Administration on
466 the Human Normal Intestinal Microbiota Using Culture and Pyrosequencing Methods. *Clin*
467 *Infect Dis* **60 Suppl 2**, S77-84 (2015).
468 12. Kabbani, T. A. *et al.* Prospective randomized controlled study on the effects of
469 Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the
470 gut microbiota of healthy volunteers. *Gut Microbes* **8**, 17–32 (2017).
471 13. MacPherson, C. W. *et al.* Gut Bacterial Microbiota and its Resistome Rapidly Recover
472 to Basal State Levels after Short-term Amoxicillin-Clavulanic Acid Treatment in Healthy
473 Adults. *Sci Rep* **8**, 11192 (2018).
474 14. Shono, Y. *et al.* Increased GVHD-related mortality with broad-spectrum antibiotic use
475 after allogeneic hematopoietic stem cell transplantation in human patients and mice. *Sci*
476 *Transl Med* **8**, 339ra71 (2016).
477 15. Slimings, C. & Riley, T. V. Antibiotics and hospital-acquired Clostridium difficile
478 infection: update of systematic review and meta-analysis. *J Antimicrob Chemother* **69**, 881–
479 891 (2014).
480 16. Deshpande, A. *et al.* Community-associated Clostridium difficile infection and
481 antibiotics: a meta-analysis. *J Antimicrob Chemother* **68**, 1951–1961 (2013).
482 17. Sullivan, A., Edlund, C. & Nord, C. E. Effect of antimicrobial agents on the ecological
483 balance of human microflora. *Lancet Infect Dis* **1**, 101–114 (2001).

484 18. Burdet, C. *et al.* Impact of Antibiotic Gut Exposure on the Temporal Changes in
485 Microbiome Diversity. *Antimicrob Agents Chemother* **63**, e00820-19 (2019).
486 19. Dethlefsen, L., Huse, S., Sogin, M. L. & Relman, D. A. The pervasive effects of an
487 antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. *PLoS Biol*
488 **6**, e280 (2008).
489 20. Jakobsson, H. E. *et al.* Short-term antibiotic treatment has differing long-term
490 impacts on the human throat and gut microbiome. *PLoS One* **5**, e9836 (2010).
491 21. Anthony, W. E. *et al.* Acute and persistent effects of commonly used antibiotics on
492 the gut microbiome and resistome in healthy adults. *Cell Rep* **39**, 110649 (2022).
493 22. Worby, C. J. *et al.* Gut microbiome perturbation, antibiotic resistance, and
494 Escherichia coli strain dynamics associated with international travel: a metagenomic
495 analysis. *Lancet Microbe* **4**, e790–e799 (2023).
496 23. Boolchandani, M., D'Souza, A. W. & Dantas, G. Sequencing-based methods and
497 resources to study antimicrobial resistance. *Nat Rev Genet* **20**, 356–370 (2019).
498
499

Table 1

	Healthy volunteers (n=33)	General medical patients (n=91)	HCT patients (n=101)	All participants (n=225)
Age, years (median, IQR)	37 (31-49)	76 (67-83)	58 (50-66)	64 (50-73)
Sex (n, %)				
Male	7 (21%)	53 (58%)	60 (59%)	120 (53%)
Female	26 (79%)	38 (42%)	41 (41%)	105 (47%)
Recent antibiotic use (n, %)				
Receiving antibiotics at time of sampling	0 (0%)	55 (60%)	42 (42%)	97 (43%)
Use in past month (but not at time of sampling)	3 (9%)	26 (29%)	22 (22%)	51 (24%)
Use in past year (but not in past month)	4 (12%)	6 (7%)	33 (33%)	43 (19%)
No antibiotics in past year	26 (79%)	4 (4%)	4 (4%)	34 (15%)
Max Charlson index in past year (median, IQR)*	0 (0-0)	4 (0-13)	0 (0-8)	0 (0-8)
Maximum values in past 14 days (median, IQR)				
NEWS2*	0 (0-0)	5 (2-8)	3 (2-4)	3 (1-5)
C-reactive protein†	0.2 (0.2-0.2)	63 (22-163)	10 (3-69)	21 (2-81)
White cell count‡	7.5 (7.5-7.5)	11.5 (8.4-14.4)	7.6 (5.8-10.9)	8.4 (7.4-12.4)
Days of chemotherapy at time of sampling (median, IQR)	0 (0-0)	0 (0-0)	3.0 (1.4-7.2)	0 (0-2.8)

* National Early Warning Score 2. Imputed as 0 if no observations recorded, see Methods.

† Imputed as 0.2 if no result recorded

‡ Imputed as 7.5 if no result recorded

Characteristics of participants in cross-sectional analysis

Figure 1 - Independent effect of specific antimicrobial exposures on Shannon diversity in A) cross-sectional, and B) longitudinal analyses. Multivariable estimates are in black, univariable (unadjusted) estimates in grey. Error bars represent 95% confidence intervals. Non-antimicrobial covariates are not shown but were included in the model and can be found in supplementary data. Results are not plotted for 4 antimicrobials (n = 6-12) that had standard errors >3 and did not differ significantly from zero. Estimates represent the impact of prolonged use, when exposure ≈ 1 (approximately 42 days, see Supplementary Figure 2).



Figure 2 - Independent effects of specific antimicrobial exposures on relative abundance of selected taxa in A) cross-sectional, and B) longitudinal multivariable analyses. Error bars represent 95% confidence intervals. Non-antimicrobial covariates are not shown but were included in the model and can be found in supplementary data. Estimates represent the impact of prolonged use, when exposure ≈ 1 (approximately 42 days, see Supplementary Figure 2).



Figure 3 - Independent effects of specific antimicrobial exposures on relative abundance of selected AMR genes in A) cross-sectional, and B) longitudinal multivariable analyses. Error bars represent 95% confidence intervals. Non-antimicrobial covariates are not shown but were included in the model and can be found in supplementary data. Estimates represent the impact of prolonged use, when exposure ≈ 1 (approximately 42 days, see Supplementary Figure 2).